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Abstract
Background: Neurofibromatosis type 2 (NF2) is an autosomal dominant syndrome
with a frequency of 1 in 25,000 live births and a penetrance of almost 100% by
the sixth decade of life. The main tumors occurring in NF2 patients are bilateral
vestibular schwannomas, other peripheral, cranial and spinal nerve schwannomas,
intracranial and intraspinal meningiomas, ependymomas, and gliomas.
Case Description: We report the case of a 6‑year‑old boy who presented with
a 1‑month history of nausea and recurrent vomiting. Physical examination was
positive for ataxic gait and left‑sided facial nerve palsy. Family history was positive
for NF2 in the patient’s father and paternal uncle. Magnetic resonance imaging
brain revealed a solid enhancing lesion arising from the right cerebellar cortex,
which was effacing the fourth ventricles and causing hydrocephalus. Craniotomy
and excision of the lesion were performed. Histopathology report confirmed the
diagnosis to be desmoplastic medulloblastoma. Based on the patients’ subsequent
history and family history, he was diagnosed to be a case of NF2.
Conclusion: This is the first case of medulloblastoma occurring in a patient with
NF2 and raises the possibility of an association between medulloblastoma and NF2.
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BACKGROUND
Neurofibromatosis type 2 (NF2) is an autosomal
dominant syndrome with a frequency of 1 in 25,000 live
births and a penetrance of almost 100% by the sixth
decade of life.[2] It has a variable presentation, resulting
from the mutation in the tumor suppressor gene
merlin, which is located on chromosome 22q, and
is a predominantly intracranial condition with its
characteristic bilateral vestibular schwannomas.[15] The
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other main tumors occurring in NF2 patients are other
peripheral, cranial and spinal nerve schwannomas,
intracranial and intraspinal meningiomas, ependymomas
and gliomas.[6] Four large clinical studies have been
conducted which confirm the aforementioned clinical
picture.[4,10,11,12] These tumors are mostly benign and
grow slowly, but their location within the central nervous
system can cause great morbidity and mortality.[9]
Clinical presentation of most patients with NF2 includes
hearing loss which is usually unilateral, with or without
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tinnitus.[6] NF2 is diagnosed clinically after a patient
fulfills a predefined criteria.[5]
Herein, we report a case NF2 presenting with recurrent
vomiting and headache that was diagnosed with
medulloblastoma. This, to the best of our knowledge,
is the first case of medulloblastoma occurring in an
NF2 patient.

CASE REPORT
A 6‑year‑old boy of average height and weight presented
to the ER in 2003 with complaints of repeated vomiting
and headache for 1‑month. He was a student of a
local public school, his past medical history being
unremarkable; his immunization status was complete,
and there were no known allergies. In family history, the
patient’s father and uncle (father’s brother) were known
to have NF2. On physical examination, he was vitally
stable. Positive findings included left‑sided facial nerve
palsy and ataxic gait.
After a series of initial investigations, magnetic resonance
imaging (MRI) brain was done. The report described
a solid mass arising from the right cerebellar cortex,
which was isointense to the gray matter on T1‑weighted
images and hypo to isointense to the gray matter on
T2‑weighted images. Postcontrast images showed an
intense enhancement, which was almost homogenous.
The mass was causing effacement of the fourth ventricles
with dilatation of the third and lateral ventricles. The
vertical height of the lesion was 4.2 cm; AP dimension
was 4 cm, and the transverse diameter was 4.8 cm. There
was no evidence of intracranial hemorrhage. Gray and
white matter signals of supratentorial brain were within
normal limits. No midline structural defect was seen. The
differential diagnoses of medulloblastoma or astrocytoma
were made.
The patient underwent craniotomy and excision of
the lesion with the insertion of a ventriculoperitoneal
shunt. The histopathology report described a malignant
infiltrating tumor present in sheets [Figure 1]. The tumor
was composed of small oval to indented basophilic cells,
exhibiting nuclear hyperchromasia [Figures 1 and 2].
Extensive necrosis [Figure 3] and karyorrhexis were identified
with areas of hemorrhage. Brisk mitotic figures were also
seen [Figure 4]. The tumor cells showed positivity for
immunohistochemical stain CD 56 [Figure 5]. Focal
positivity for immunohistochemical stain glial fibrillary
acidic protein was also seen [Figure 6]. Based on these
findings a final diagnosis of desmoplastic medulloblastoma
was made.
The patient underwent metastatic workup which was
negative. After discharge, he was kept under close
follow‑up. Pediatric oncology team was taken on board
and after discussing the case at the tumor board meeting,

Figure 1: Patternless sheets of primitive appearing neoplastic cells
with hyperchromatic nuclei with neuropil

Figure 2: Primitive appearing neoplastic cells with hyperchromatic
nuclei, scant cytoplasm, and indistinct cell borders

Figure 3: Tumor with areas of necrosis as indicated by the arrow
(H and E, ×20)

a multidisciplinary approach was taken and both
chemotherapy and radiotherapy were administered.
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with histopathology of the lesion revealing benign
peripheral nerve sheath tumor.
In 2004, during a routine MRI scan the patient was
found to have a cerebellar lesion for which he underwent
craniotomy and excision of the lesion. Biopsy of the
excised specimen revealed postchemotherapy and
radiotherapy gliosis. He was then again kept under close
follow‑up. He complained of vision disturbances in
2006 and after an ophthalmological exam, was diagnosed
to have right eye cataract for which he underwent
phacoemulsification and insertion of the intraocular lens.

Figure 4: Neoplastic cells showing prominent mitotic figures as
pointed out by the arrow (H and E, ×40)

Till 2010, his routine follow‑up MRI scans showed no
significant pathological changes. However, in 2010, he
again started complaining of vision disturbances and
ophthalmological examination revealed right‑sided
posterior capsular opacification and left‑sided cataract.
He underwent left capsulectomy.
Over the span of next 3 years the patient remained
well however, in 2013, he was again brought to Aga
Khan University Hospital with complaints of headache,
vomiting, and gait disturbances. MRI brain showed right
superior frontal, inferior frontal, parasagittal and left
posterior parietal meningiomas; excision of the lesions
was performed.
Considering his case history and his family history, a
diagnosis of NF2 was considered for him. A neurologist
was taken on board; the NIH criterion was applied, and
the patient was diagnosed to have NF2.

Figure 5:Tumor cells showing positivity for immunohistochemical
stain CD56

After the surgery in 2013, the patient has not been
reported any symptoms. The follow‑up MRI scans have
not revealed any positive findings.

DISCUSSION
NF is a genetic disorder of the nervous system. It became
widely recognized in the 19th century,[1] but it has a wide
pictorial history that traces back to the 13th century.[3]
The neuromas of NF were first described, in 1849.[3] Von
Recklinghausen’s is credited with the discovery of NF
and coined the name of this disorder, in 1882.[3] Research
on NF increased between 1909 and 1990 after Joseph
Merick, the famous Elephant Man, was erroneously
diagnosed with NF1.[3]

Figure 6:Tumor cells showing focal positivity for immunohistochemical
stain glial fibrillary acidic protein

In 2003, he was found to have a 1.0 cm × 1.5 cm skin
colored nodule on this left forearm, which was excised
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NF is considered to have two distinct types, NF1 and
NF2.[14] NF1 has more peripheral manifestations and
NF2 carries predominantly central manifestations. Over
the past two decades, our knowledge of the genetics
and management of NF has dramatically increased. The
two forms of NF have been shown to be two distinct
entities, both at clinical and molecular levels.[14] NF
also has other rarer forms with outlying phenotypes and
atypical presentations. These unconventional and atypical
forms have been delineated and include hereditary spinal
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NF, schwannomatosis, familial intestinal NF, autosomal
dominant “café au lait” spots alone, Watson syndrome,
autosomal dominant “neurofibromas” alone, Noonan
syndrome and the syndrome of multiple naevi, multiple
schannomas, and multiple vaginal leiomyomas.[14]
NF2 is often a devastating autosomal dominant disorder
which until recently was confused with its more common
namesake NF1.[6] NF2 is a multiple neoplasia syndrome
that results from a mutation in NF2 tumor suppressor
gene on chromosome 22.[2] Affected patients carry a
dominant loss of function mutation of the merlin gene
on chromosome 22. Merlin is a cytoskeletal protein
that functions as a tumor suppressor by facilitating
E‑cadherin‑mediated contact inhibition.
NF2 inevitably develops schwannomas, typically affecting
both the vestibular nerves, resulting in hearing loss and
deafness. Most of the patients present with hearing loss
which is unilateral at onset and may be accompanied
or preceded by tinnitus.[7] Vestibular schannomas may
also cause dizziness or imbalance as first symptoms.
Nausea, vomiting or true vertigo are rare symptoms,
occurring more commonly in the later stages.[7] The
other tumors seen in NF2 are schwannomas of other
cranial, spinal, and peripheral nerves. Furthermore,
NF2 is associated with intracranial and intraspinal
meningiomas and low‑grade central nervous system
malignancies like ependymomas.[7] As mentioned
previously, both meningiomas and schwannomas were
seen in our patient. Ophthalmic manifestations are also
present in NF2 and include reduced juvenile cataracts,
as seen in our patient, and retinal hamartomas.[8] About
70% of NF2 cases have skin tumors with intracutaneous
plaque like lesions or more deep‑seated tumors.[7]
Medulloblastoma is an aggressive posterior fossa brain
tumor. Although medulloblastoma has been reported in
patients with NF1, one study found the prevalence of
posterior fossa tumors in NF1 to be 0.83%, there is no
reported case of medulloblastoma occurring in a patient
with NF2.[13]

To the best of our knowledge, this is the first case of
medulloblastoma in a patient with NF2. The literature
review conducted for this report could not find any case
report or research study relating medulloblastoma and
NF2. This raises the possibility of an association between
these two disease entities and shows that even NF2 can
also have this posterior fossa brain stem tumor.
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